Phase 2 study for improvement of prostate cancer diagnosis

Prostate cancer awareness month may already be over, but men’s health remains an important topic. We are therefore most pleased to announce that ABX-CRO was chosen to collaborate with Curasight in a phase 2 study to improve the diagnosis of prostate cancer. The...

TRP EU in December 2023

We are happy to announce that our last conference this year will be the Targeted Radiopharmaceuticals Summit Europe. Come and find us in Berlin from 5 to 7 December. Join us for our talks: “Using multiple legislations to optimise clinical trial conduct (EU & USA)”...

ABX-CRO at EANM’23

On to the next congress – from September 9-13 we will head to Vienna to be part of the 36th Annual Congress of the European Association of Nuclear Medicine – the EANM’23. The EANM industrial exhibition gives an extensive overview of the latest achievements in...

TRP US 2023 and AGRR

After returning from a successful SNMMI in Chicago, we are now excited to participate in the second Targeted Radipharmaceuticals Summit US – the TRP US. Moritz Kallerhoff, ABX-CRO INC.’s Chief Executive Officer, will be on site for us in Boston from July...

ABX-CRO goes SNMMI 2023

Once again we will be attending the premier event for education, science, research and networking in nuclear medicine and molecular imaging – SNMMI 2023 – you will find us in Chicago, Illinois, June 24-27, Booth #3082. We have been an almost annual...
Untitled Document